

# Opportunity Cost of Funding Drugs for Rare Diseases

Medical Decision Making

34, 1016-1029

DOI: [10.1177/0272989x14539731](https://doi.org/10.1177/0272989x14539731)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 92.	1.2	53
2	Eculizumab use in kidney transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, Publish Ahead of Print, 643-51.	0.8	24
3	Eculizumab for aHUS post-transplantation: when and how to stop a good thing. <i>Transplant International</i> , 2015, 28, 1000-1001.	0.8	0
4	Oxidative stress in paroxysmal nocturnal hemoglobinuria and other conditions of complement-mediated hemolysis. <i>Free Radical Biology and Medicine</i> , 2015, 88, 63-69.	1.3	15
5	The Need for Transparency and Efficiency in Reimbursement Decisions Relating to Drugs for Rare Diseases. <i>Medical Decision Making</i> , 2015, 35, 145-147.	1.2	0
6	Importance of Transparency in Assessing the Feasibility of Modeling Rare Disease. <i>Medical Decision Making</i> , 2015, 35, 143-144.	1.2	1
7	Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 72.	1.2	49
8	PASylated Coversin, a C5-Specific Complement Inhibitor with Extended Pharmacokinetics, Shows Enhanced Anti-Hemolytic Activity in Vitro. <i>Bioconjugate Chemistry</i> , 2016, 27, 2359-2371.	1.8	53
9	New milestones ahead in complement-targeted therapy. <i>Seminars in Immunology</i> , 2016, 28, 208-222.	2.7	92
10	The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption. <i>Expert Review of Proteomics</i> , 2016, 13, 241-243.	1.3	9
11	Eculizumab for the treatment of hemolytic paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and refractory myasthenia gravis. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 375-379.	0.5	1
12	Eculizumab cessation in atypical hemolytic uremic syndrome. <i>Blood</i> , 2017, 130, 368-372.	0.6	70
13	Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics. <i>Journal of Immunology</i> , 2017, 198, 3705-3718.	0.4	11
14	Development of Autologous C5 Vaccine Nanoparticles to Reduce Intravascular Hemolysis <i>in Vivo</i> . <i>ACS Chemical Biology</i> , 2017, 12, 539-547.	1.6	17
15	Pharmacologic Hemostatic Agents in Total Joint Arthroplasty – A Cost-Effectiveness Analysis. <i>Journal of Arthroplasty</i> , 2018, 33, 2092-2099.e9.	1.5	14
16	Estimating the opportunity costs of bed days. <i>Health Economics (United Kingdom)</i> , 2018, 27, 592-605.	0.8	31
17	Economic Evaluation of Stiripentol for Dravet Syndrome: A Cost-Utility Analysis. <i>Pharmacoeconomics</i> , 2018, 36, 1253-1261.	1.7	16
18	Identification of complement inhibitory activities of two chemotherapeutic agents using a high-throughput cell imaging-based screening assay. <i>Molecular Immunology</i> , 2018, 101, 86-91.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. <i>Journal of Molecular Medicine</i> , 2018, 96, 965-974.	1.7	5
20	Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 15.	1.2	25
21	Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. <i>Haemophilia</i> , 2018, 24, 60-67.	1.0	35
22	Immunosuppressants in Brazil: underlying drivers of spending trends, 2010â€“2015. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 565-572.	0.7	8
23	Healthcare Rationing Cutoffs and Sorites Indeterminacy. <i>Journal of Medicine and Philosophy</i> , 2019, 44, 479-506.	0.4	3
24	Economic evaluation of deep-brain stimulation for Touretteâ€™s syndrome: an initial exploration. <i>Journal of Neurology</i> , 2019, 266, 2997-3008.	1.8	0
25	Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071987472.	1.1	50
26	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1331-1339.	2.0	17
27	The Extended Use of Eculizumab in Pregnancy and Complement Activationâ€™Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now?. <i>Journal of Clinical Medicine</i> , 2019, 8, 407.	1.0	25
28	Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. <i>Clinical Pharmacokinetics</i> , 2019, 58, 859-874.	1.6	82
29	Evaluating Canadiansâ€™ Values for Drug Coverage Decision Making. <i>Value in Health</i> , 2019, 22, 362-369.	0.1	16
30	Treatment of antiphospholipid syndrome beyond anticoagulation. <i>Clinical Immunology</i> , 2019, 206, 53-62.	1.4	23
31	Paces of Costly Care: Rare Disease Drug Access in Canada. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2020, 39, 319-332.	0.6	3
32	Opportunities and barriers for innovation and entrepreneurship in orphan drug development. <i>Technological Forecasting and Social Change</i> , 2020, 161, 120333.	6.2	5
33	Eculizumab in the treatment of neuromyelitis optica spectrum disorder. <i>Immunotherapy</i> , 2020, 12, 1053-1066.	1.0	7
34	A crisis in <sc>US</sc> drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2. <i>Muscle and Nerve</i> , 2020, 62, 573-578.	1.0	5
35	Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. <i>Frontiers in Immunology</i> , 2020, 11, 599417.	2.2	31
36	Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?. <i>Pharmacoeconomics</i> , 2020, 38, 777-779.	1.7	5

#	ARTICLE	IF	CITATIONS
37	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. <i>European Journal of Health Economics</i> , 2020, 21, 845-853.	1.4	1
38	Clinical and Economic Impact of Ibalizumab for People With Multidrug-Resistant HIV in the United States. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 148-156.	0.9	14
39	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. <i>Blood</i> , 2021, 137, 969-976.	0.6	46
40	A systematic review of moral reasons on orphan drug reimbursement. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 292.	1.2	17
41	Methodology for constructing scenarios for health policy research: The case of coverage decision-making for drugs for rare diseases in Canada. <i>Technological Forecasting and Social Change</i> , 2021, 171, 120960.	6.2	2
42	Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria From the Perspective of the Brazilian Public Health System. <i>Value in Health Regional Issues</i> , 2021, 26, 113-125.	0.5	0
43	The renaissance of complement therapeutics. <i>Nature Reviews Nephrology</i> , 2018, 14, 26-47.	4.1	305
46	Proposal for individualized dosing of eculizumab in atypical haemolytic uraemic syndrome: patient friendly and cost-effective. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 362-371.	0.4	3
47	Novel Complement C5 Small-interfering RNA Lipid Nanoparticle Prolongs Graft Survival in a Hypersensitized Rat Kidney Transplant Model. <i>Transplantation</i> , 2022, 106, 2338-2347.	0.5	6
48	Efficacy and safety of current treatments for Paroxysmal Nocturnal Hemoglobinuria: A systematic review. <i>Clinical Immunology Communications</i> , 2022, , .	0.5	1
49	A phase III, randomised, double-blind, multinational clinical trial comparing SB12 (proposed eculizumab) Tj ETQq0 0 0 rgBT /Overlo 2023, 4, 26-36.	0.4	3
50	Paroxysmal nocturnal hemoglobinuria: Where we stand. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	3
52	Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies. <i>Pharmacoeconomics</i> , 0, , .	1.7	0